Emerging Therapies in Oncology: Tumor-Infiltrating Lymphocytes

Mar 6, 2025

Author(s):

BioPharm International® spoke with Jason Bock, founder and CEO of CTMC, to find out about the newest cancer treatments, specifically developments in tumor-infiltrating lymphocytes.

Access article: BioPharm International

Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

May 7, 2026

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...

Part 1: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

May 5, 2026

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...

Base to Base biotech podcast #55: The circular supply chain

Apr 17, 2026

CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change...

Back

Emerging Therapies in Oncology: Tumor-Infiltrating Lymphocytes

Recent News

Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

Part 1: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

Base to Base biotech podcast #55: The circular supply chain

Explore CTMC

Resources + Support

Contact Us